Clinical and research tests for C1838547 - Genetic Testing Registry (GTR) - NCBI

Warning: The NCBI web site requires JavaScript to function. more...

<< First< Prev

Page 1 of 3

Results: 1 to 20 of 59

Tests names and labs	Conditions	Genes, analytes, and microbes	Methods
Hereditary Prostate Cancer Panel QDx Pathology Services, Inc. United States	4	16	D Deletion/duplication analysis C Sequence analysis of the entire coding region
Clariti 20/20 QDx Pathology Services, Inc. United States	15	44	D Deletion/duplication analysis C Sequence analysis of the entire coding region
Hereditary Pancreatic Cancer Panel Clariti Diagnostics Laboratories LLC United States	4	15	D Deletion/duplication analysis C Sequence analysis of the entire coding region
Clariti 20/20 Clariti Diagnostics Laboratories LLC United States	15	44	D Deletion/duplication analysis C Sequence analysis of the entire coding region
Hereditary Cancer Panel Comprehensive Molecular Genetics Laboratory London Health Sciences Centre Canada	39	30	D Deletion/duplication analysis C Sequence analysis of the entire coding region T Targeted variant analysis
PREVENTEST GeneID Lab - Advanced Molecular Diagnostics United States	60	34	D Deletion/duplication analysis C Sequence analysis of the entire coding region
Hereditary Cancer Panel - High Penetrance 16 Molecular Genetics Laboratory London Health Sciences Centre Canada	28	16	D Deletion/duplication analysis E Sequence analysis of select exons C Sequence analysis of the entire coding region
Common Hereditary Cancer Screening Panel PreventionGenetics United States	94	55	D Deletion/duplication analysis C Sequence analysis of the entire coding region T Targeted variant analysis
myRisk Hereditary Cancer Myriad Genetics, Inc. United States	32	46	D Deletion/duplication analysis C Sequence analysis of the entire coding region
CentoColon Centogene AG - the Rare Disease Company Germany	67	33	D Deletion/duplication analysis C Sequence analysis of the entire coding region
CentoCancer Centogene AG - the Rare Disease Company Germany	114	68	D Deletion/duplication analysis C Sequence analysis of the entire coding region
CentoCancer Comprehensive Centogene AG - the Rare Disease Company Germany	156	107	D Deletion/duplication analysis C Sequence analysis of the entire coding region
CDKN2A - NGS including CNV analysis Centogene AG - the Rare Disease Company Germany	3	1	D Deletion/duplication analysis C Sequence analysis of the entire coding region
Invitae Common Hereditary Cancers + RNA Panel Invitae United States	114	47	D Deletion/duplication analysis
CancerNext® 37 Ambry Genetics United States	79	37	D Deletion/duplication analysis C Sequence analysis of the entire coding region
Variant Resolution Test for CancerNext® 37 (+RNAinsight®) Ambry Genetics United States	79	18	D Deletion/duplication analysis R RNA analysis C Sequence analysis of the entire coding region
Variant Resolution Test for Penn Cancer Grant Panel (+RNAinsight®) Ambry Genetics United States	79	18	D Deletion/duplication analysis C Sequence analysis of the entire coding region
Penn Cancer Grant Panel Ambry Genetics United States	79	80	D Deletion/duplication analysis C Sequence analysis of the entire coding region
Pancreatic cancer/melanoma syndrome, 606719, Autosomal dominant (Familial atypical multiple mole melanoma syndrome) (MLPA) Intergen Intergen Genetics and Rare Diseases Diagnosis Center Turkey	1	1	D Deletion/duplication analysis
Variant Resolution Test for CancerNext® (+RNAinsight®) Ambry Genetics United States	79	18	D Deletion/duplication analysis R RNA analysis C Sequence analysis of the entire coding region

<< First< Prev

Page 1 of 3

Results: 1 to 20 of 59

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.